<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04295213</url>
  </required_header>
  <id_info>
    <org_study_id>NL70820.081.19</org_study_id>
    <nct_id>NCT04295213</nct_id>
  </id_info>
  <brief_title>The Inside Study II: Oligosaccharides Versus Placebo and Hard Stools</brief_title>
  <official_title>The Effect of a Oligosaccharides Versus a Placebo on Defecation Parameters in Healthy Children With Hard or Lumpy Stools</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wageningen University and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>FrieslandCampina, Amersfoort, The Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wageningen University and Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the present randomised double blind controlled study, we will study the effects of a
      oligosaccharides vs a placebo on the change in stool consistency and stool frequency in
      children with hard or lumpy stools.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Firm, hard or lumpy stools can be problematic for young children and might come as a
      precursor of functional constipation in childhood. The cause of harder stools in childhood is
      incompletely understood. But it is likely that harder stools in childhood are linked to among
      others withholding behaviour of stools and a low fibre intake. As hard stools may precede
      functional constipation, the aim of the study is to investigate the effect of a prebiotic
      fiber versus a placebo on defecation parameters in healthy children with hard or lumpy
      stools. We hypothesize that consumption of a prebiotic fiber results in softer stools.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel study with two arms of 13 weeks in total per participant</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stool consistency</measure>
    <time_frame>Stool consistency will be measured at different time points during a study period of 13 weeks.</time_frame>
    <description>Change in stool consistency measured by the a stool questionnaire; 5 points stool scale from 1 hard to 5 watery (modified Bristol Stool Form Scale)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stool frequency in number of cases (%)</measure>
    <time_frame>These outcome measures will be measured at different time point during a study period of 13 weeks.</time_frame>
    <description>Stool frequency - number of times a child has stools a day as reported in a diary.by a stool questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool consistency in number of cases (%)</measure>
    <time_frame>These outcome measures will be measured at different time point during a study period of 13 weeks.</time_frame>
    <description>Stool consistency - % of stools in a certain stool scale score as measured via a 5 point stool scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">196</enrollment>
  <condition>Healthy With Hard and/or Lumpy Stools</condition>
  <arm_group>
    <arm_group_label>oligosaccharide group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intervention with oligosaccharides, total duration of study is 13 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator, total duration of study is 13 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>oligosaccharides</intervention_name>
    <description>1 dose a day of oligosaccharides or placebo</description>
    <arm_group_label>oligosaccharide group</arm_group_label>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  aged 1-3 years

          -  Hard and/or firm stools as scored by a stool questionnaire

        Exclusion Criteria:

          -  Children that meet the Rome IV criteria for functional constipation

          -  Children who suffer from any other GI complaints, known structural GI abnormalities,
             or previous GI surgery

          -  Any condition that would make it unsafe for the child to participate.

          -  Children with clinically significant cardiac, vascular, liver, pulmonary, psychiatric
             disorders, severe renal insufficiency, human immunodeficiency virus, acquired
             immunodeficiency syndrome, hepatitis B or C or known abnormalities of haematology,
             urinalysis, or blood biochemistry, as checked by the inclusion questionnaire.

          -  Children who are allergic to cow's milk or fish

          -  Use of antibiotics or other medicines or food supplements, and breast milkfeeding,
             which can influence defecation and gut microbiota 4 weeks prior to the study

          -  Children that participate in another clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>3 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clara Belzer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wageningen University and Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc Benninga, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emma Children's Hospital, UMC Amsterdam</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clara Belzer, PhD</last_name>
    <phone>0031317-483 742</phone>
    <email>clara.belzer@wur.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carrie Wegh, MSc</last_name>
    <email>carrie.wegh@wur.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wageningen University and Research</name>
      <address>
        <city>Wageningen</city>
        <state>Gelderland</state>
        <zip>6708 WE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie A.M. Wegh, MSc</last_name>
      <phone>00316-39267118</phone>
      <email>carrie.wegh@wur.nl</email>
    </contact>
    <contact_backup>
      <last_name>Clara Belzer, PhD</last_name>
      <email>clara.belzer@wur.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>March 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2020</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wageningen University and Research</investigator_affiliation>
    <investigator_full_name>Clara Belzer</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>oligosaccharides</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

